Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Columbia Pipeline Partners LPCPPL · Entity 178626 | Director | February 17, 2017 | February 22, 2017 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 06, 2025 | May 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Columbia Pipeline Partners LP
Report date February 17, 2017 · Filed February 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common units (limited partner interests)SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-02-17 transaction · row 1
1 source rowRow 1 · 2017-02-17 · Disposition to issuer · Disposed 16,092 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 1, 2016, by and among Columbia Pipeline Partners LP (the "Issuer"), CPP GP LLC, a Delaware limited liability company and the general partner of the Issuer, Columbia Pipeline Group, Inc., a Delaware corporation ("CPG"), and Pony Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of CPG, each common unit held by the reporting person was canceled and converted into the right to receive $17.10416 in cash, without interest, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of November 1, 2016, by and among Columbia Pipeline Partners LP (the "Issuer"), CPP GP LLC, a Delaware limited liability company and the general partner of the Issuer, Columbia Pipeline Group, Inc., a Delaware corporation ("CPG"), and Pony Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of CPG, each common unit held by the reporting person was canceled and converted into the right to receive $17.10416 in cash, without interest, less any applicable withholding taxes.
WEST PHARMACEUTICAL SERVICES INC
Report date May 06, 2025 · Filed May 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,637.12 |
Reported balance
After 2025-05-06 transaction · row 1
1 source rowRow 1 · 2025-05-06 · Grant · Acquired 1,071 · Balance 44,637.12 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2025 Filed May 8, 2025 20:35 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013704 · form4.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,637.12 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 10, 2024 Filed Aug 21, 2024 20:51 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 617 | $365.92 | $225,772.64 |
DisclosureSEC source: 0001127602-24-022722 · form4.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,564.68 Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:15 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013392 · form4.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,180.39 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,212 | $365.58 | $443,076.90 |
DisclosureSEC source: 0001562180-23-003796 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,616.39 F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $365.52 to $365.64, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-003705 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,828.39 F1 · price: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004431 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,212.39 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 04, 2021 Filed May 6, 2021 23:29 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-003311 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,580.39 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-003462 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,886.142 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 07, 2019 Filed May 9, 2019 19:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-002734 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,815.708 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:48 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002199 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,250.708 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 02, 2017 Filed May 3, 2017 18:48 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001681 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,426.708 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:12 UTC | Columbia Pipeline Partners LP CPPL · Entity 178626 | Disposition to issuerCommon units (limited partner interests) | 16,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008573 · doc1.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of November 1, 2016, by and among Columbia Pipeline Partners LP (the "Issuer"), CPP GP LLC, a Delaware limited liability company and the general partner of the Issuer, Columbia Pipeline Group, Inc., a Delaware corporation ("CPG"), and Pony Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of CPG, each common unit held by the reporting person was canceled and converted into the right to receive $17.10416 in cash, without interest, less any applicable withholding taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.